Regulus Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Regulus Therapeutics

11/11/2021 01:18

* Regulus Therapeutics Inc  RGLS.OQ  reported a quarterly
adjusted loss of 10 cents​​ per share for the quarter ended in
September. The mean expectation of four analysts for the quarter
was for a loss of 8 cents per share.
* Reported revenue was zero​;  analysts expected $4.50
thousand. 
* Regulus Therapeutics Inc's reported EPS for the quarter was a
loss of 10 cents​.
* The mean earnings estimate of analysts had risen by about 3.1%
in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Regulus Therapeutics Inc shares had fallen by 33.0% this
quarter and lost 65.7% so far this year.
* The company reported a quarterly loss of $8.63 million.
* Wall Street's median 12-month price target for Regulus
Therapeutics Inc is $1.50 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
This summary was machine generated November 11 at 01:18 a.m.
 ​All figures in US dollars unless otherwise stated